Methods
The CARRA Legacy Registry is a multicenter registry developed in North America to capture information about multiple rheumatic diseases, including juvenile idiopathic arthritis, mixed connective tissue disease, systemic lupus erythematosus, juvenile dermatomyositis, vasculitis, scleroderma, sarcoidosis, and primary juvenile fibromyalgia. It includes subjects with diagnosed rheumatic diseases from 55 pediatric CARRA centers in North America between May 2010 and July 2014. It is an observational data capture registry representing a convenience sample of eligible subjects. Institutional Review Board approval was obtained at each enrolling site. Each subject and/or a parent/legal guardian provided informed consent (in English or Spanish).
Subjects were eligible for inclusion who were aged <21 years with onset of JDM before age 18 years and met the definite criteria for JDM as defined by modified Bohan and Peter criteria. Bohan and Peter criteria were modified by the CARRA Legacy Registry project investigators to include MRI as an acceptable diagnostic modality for JDM, to reflect common practice and increase inclusion. Subjects could be at any disease stage and were not required to be recently or newly diagnosed. Subjects were excluded from our analysis if age of onset could not be clearly identified as before 18 years or if they did not meet the criteria for a diagnosis of definite JDM by these modified standards 4, 5 : classic skin involvement for JDM and at least 3 of the following: muscle weakness, elevated muscle enzyme levels, abnormal EMG suggestive of inflammatory myopathy, abnormal muscle biopsy suggestive of inflammatory myopathy, or MRI evidence of myositis (modification introduced by CARRA Legacy Registry investigators 21 ).
Data Collection
Clinical data were collected from the subjects/guardians and the enrolling physicians using both general and JDM-specific case report forms at the time of enrollment. In addition, the subject's medical records were reviewed for previously obtained disease-specific clinical information. Subjects diagnosed before May 2010 were recruited retrospectively. Data were pooled and stored in a secure centralized electronic database and deidentified before analysis.
Demographic and Baseline Information
Baseline demographic information was obtained by the enrolling physician. Family income was based on self-report from the parent or guardian of the enrolled subject. Medical insurance status was recorded by the enrolling physician as yes or no. No information was collected regarding public or private sources of insurance, or coinsurance. Racial/ethnic background was self-identified by the subject or parent/guardian during enrollment. For the purpose of this study, subjects who self-identified as white and not biracial were classified as white, those who self-identified as black or black and biracial were classified as black, and all others were classified as minority, nonblack. Subjects without race identified were dropped from the analysis (n = 3). Treatment history was recorded by the enrolling physician from chart abstraction or other records. Disease duration at enrollment was calculated as age at onset of symptoms subtracted from the age at enrollment. A delay in diagnosis was as >12 months from the onset of symptoms to the first appointment with a pediatric rheumatologist. Annual family income was reported by subjects in increments of $25 000. We compared patient characteristics according to reported annual family income, using a cutoff of greater or less than $50 000, which is closest to the lowincome threshold for a US family of 4 with 2 children.
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Outcome Measures
For each subject, data were collected on muscle strength, physical functioning, and quality of life. The Childhood Myositis Assessment Scale (CMAS) score (maximum score, 52), the Childhood Health Assessment Questionnaire (CHAQ) score (ranging from 0, normal to 3, worst), health-related quality of life (HRQoL) measures, the American College of Rheumatology (ACR) functional class rating, and global disease assessments were also recorded. The CMAS has been validated to quantitatively assess muscle strength and endurance in children with idiopathic inflammatory myopathies. 21, 23, 24 The ACR functional class rating ranges from class I (able to perform usual activities of daily, living including self-care, vocational, and avocational activities) to class IV (limited ability to perform usual self-care, vocational, and avocational activities). 25 The ACR class was reported by the enrolling physician as the highest (ie, worst) class occurring during the course of the disease based on either subject report or chart abstraction. Proximal muscle weakness, rash (malar or facial erythema), Gottron rash, and calcinosis were reported as present or absent by the enrolling physician. Calcinosis served as a surrogate marker of disease morbidity.
Statistical Analyses
Statistical analysis was conducted using Stata version 10.0 (StataCorp, Austin, Texas). All data analyses were preceded by extensive data checking and verification to identify and resolve the reasons for missing values, inconsistencies, and out-ofrange values. Descriptive statistics were computed to summarize each variable, including mean ± SD or median (IQR) for continuous variables and frequency (percentage) for categorical variables. The c 2 and Kruskal-Wallis tests were used to evaluate associations among demographic characteristics, income, treatments, and disease activity with disease duration, race, and income. All tests were 2-sided, with a P value <.05 considered to indicate statistical significance.
We performed multivariate logistic regression of the outcome calcinosis, which served as a surrogate marker of disease morbidity. Variables for inclusion in the multivariate model were selected based on results from bivariate testing following a stepwise approach, with previously associated variables, such as duration of disease, sex, and delay to treatment, selected automatically. Variables significantly (P < .10) associated with calcinosis (ie, race and income) and static variables associ- add significantly to the model fit, and there was no evidence of interaction, then the variable was dropped from the model. Tests for interactions were performed using interaction terms of binary outcomes for black race, annual family income <$50 000, and ANA.
Results
Between May 2010 and July 2014, 639 subjects meeting the modified Bohan and Peter criteria for probable or definite JDM were enrolled from 55 CARRA sites. Confirmation of definite JDM by EMG, MRI, or biopsy analysis was obtained for 441 of these subjects, 438 of whom had complete racial information available. The median duration of disease from symptom onset to registry enrollment was 3.1 years (IQR, 1.2-6.2 years), and the median time to diagnosis was 4 months (IQR, 1.9-10.7 months).
Overall, 79% of the subjects (347 of 438) were identified as white, 13% (57 of 438) as black, and 8% (34 of 438) as minority, nonblack. The subjects were predominantly female (71%), with a median age of onset of 5.6 years. More than 90% of all subjects had received an oral corticosteroid and a diseasemodifying antirheumatic drug. At the time of enrollment, 10% had clinical weakness and 32% had active rash (facial erythema). In the entire cohort, the median CHAQ score was 0.12 and the median CMAS score was 50 at the time of enrollment ( Table I) .
Associations with Race and Income
Black children tended to be older at age of onset, but the difference was not statistically significant (median, 5.6 years for white, 6.4 years for black, and 5.0 years for minority, nonblack; P = .36). There were no significant differences among the racial groups in terms of sex, time to diagnosis, disease duration, and treatments (eg, IV corticosteroids, oral corticosteroids, diseasemodifying antirheumatic drugs, biologics, IV immunoglobulin, cyclophosphamide) ( Table I) .
Family income was reported for 346 subjects (79%). Black subjects were more likely than other groups to report an annual family income <$50 000. The vast majority of patients had medical insurance (97.5%, including 98.3% for white, 94.7% for black, and 94.1% for minority nonblack; P = .13). Black and minority nonblack subjects were statistically more likely to have worse CHAQ scores, patient global scores, and HRQoL scores. Physician assessment of weakness, facial erythema, and Gottron rash did not differ among the races. The worst ACR functional class also did not differ between groups. Black and minority nonblack subjects had a lower likelihood of positive ANA compared with white subjects (41.9% and 45.8%, respectively, vs 68.1% in white subjects; P < .01).
There were no measurable differences based on age of onset, sex, and median interval time onset of symptoms to the first visit with a pediatric rheumatologist based on an annual family income cutoff of $50 000 per year (Table II) . Subjects with an annual family income <$50 000 had statistically significantly worse CHAQ scores, patient global, and physician global scores, and lower HRQoL scores compared with those with an annual family income >$50 000. In addition, moderate to severe muscle weakness at the time of enrollment was more common in the subjects with an annual family income <$50 000 (10.3% vs 8.7%; P = .03), although there was no difference in weakness based on CMAS score. ACR functional class was higher (ie, worse) in the subjects with an annual family income <$50 000.
Associations with Calcinosis
Among all subjects, 15% (63 of 427) had calcinosis ( Table I) . A greater percentage of black subjects (24%; 13 of 57) had calcinosis compared with white subjects (4%) and minority nonblack subjects (9%), but the difference was not statistically significant (P = .09). A subgroup univariate analysis of black subjects found a 2-fold higher odds of calcinosis in black subjects compared with the other subjects in this cohort (OR, 2.05; 95% CI, 1.03-4.09).
Annual family income <$50 000 was associated with an OR of 1.92 (95% CI, 1.03-3.59) for calcinosis. Given the missing data regarding family income status in 21% of the subjects, we conducted a sensitivity analysis assuming that those who did not respond had an annual family income <$50 000. This assumption did not change the results. A delay to diagnosis and increased duration of disease were also independent predictors of calcinosis; 25% of the subjects diagnosed after a >12-month duration of symptoms had calcinosis.
In a multivariable analysis of calcinosis alone (Table III) , black race, time to diagnosis, and duration of disease were identified as significant independent predictors of calcinosis. We found no significant interactions between black race and positive ANA or annual family income <$50 000.
Discussion
Our analysis revealed independent health disparities in our cohort of children with JDM based on race and income. Overall, compared with the white subjects, the black and minority nonblack subjects had lower reported annual family income and lower CHAQ, HRQoL, and patient global scores, and the black subjects had a higher rate of calcinosis.
Similar results were found when comparing patient groups based on family income. We found that more minority subjects reported an annual family income of <$50 000; these subjects also had higher rates of calcinosis and worse CHAQ/ functional scores, HRQoL, weakness, and patient and physician global scores. Univariate analysis showed that lower income was associated with calcinosis, whereas multivariable analysis revealed that race, but not income, was an independent risk factor for the development of calcinosis; no effect of interaction was seen between race and annual income <$50 000. This finding does not completely rule out the possibility of interaction, but helps inform our model.
The known correlation between minority race and lower income in the US 22 was also seen in our JDM cohort. Black and minority nonblack race and low family income were associated with worse outcome measures in our cohort, but it is not clear from the available registry data and our analysis whether this correlation is due to genetic differences, environmental exposures, access to care, type of insurance, treatment THE JOURNAL OF PEDIATRICS • www.jpeds.com Volume 184 adherence, or other treatment-related and non-treatmentrelated factors.
Calcinosis was found in up to 40% of our subjects with JDM, compared with the current reported prevalence, which ranges from 10% to 70%. 7, 21, [26] [27] [28] [29] We found that a delay to diagnosis and extended duration of disease were associated with the development of calcinosis, as has been reported by others. [30] [31] [32] We found higher rates of calcinosis in the black subjects, but the overall rate of reported calcinosis in our cohort was similar to that reported previously.
7,31-33 An extremely high rate of calcinosis has been reported in an African cohort of JDM subjects, with a 70% cumulative risk of calcinosis, which is often associated with vasculitis in that patient population. 34 The rate of calcinosis in our black North American cohort, although not as high as that reported in African subjects, suggests a genetic component in the development or pathogenesis of calcinosis.
In JDM, similar to other inflammatory conditions, such as familial Mediterranean fever, systemic lupus erythematosus, and psoriatic arthritis, genetic as well as environmental factors likely contribute to expression of the disease. Some differences in autoantibodies and clinical expression of juvenile myositis have been described, such as anti-SRP antibodies, which is associated with black race, severe disease, and juvenile polymyositis. 35 Differences in immune response genes between races also have been described in JDM. 36 Thus, our findings support the concept that JDM is a multifactorial, complex autoimmune disorder with a genetic contribution.
We were encouraged to find no significant differences in treatments administered based on race or income; however, our findings of several worse outcome measures, based on race and income, suggest that there are additional factors that we are not measuring, recognizing, or treating. In addition, we suspect, similar to what has been described in other pediatric chronic conditions such as asthma, inflammatory bowel disease, and juvenile arthritis, [37] [38] [39] [40] [41] that there are differences in responses and efficacy of medications based on genetic variation. Therefore, these data suggest that improved pharmacogenetic assessment and approaches are needed to improve future outcomes in JDM. We also note that detailed data on the duration and total cumulative dose of treatments and adherence were not collected, which might have contributed to these differences in outcome measures. Overall, the majority of the subjects in this cohort had mild disease and good outcomes, including those of black race and low income.
The results of our analysis are not without limitations. The CARRA Legacy Registry might not represent the full spectrum of patients with JDM. Subjects were enrolled only from academic centers, where CARRA members, who are pediatric rheumatologists, care for patients, and might not represent a subset of patients who do not have access to care at these centers. In addition, we might have missed a subset of patients followed by other specialists, such as dermatologists and neurologists. Furthermore, the method of accrual into the registry might have influenced subject enrollment to the registry; subjects were enrolled by researchers at individual centers, and although the intent was to enroll all subjects with JDM, we cannot rule out the possibility that there was an ascertainment bias in the subjects enrolled in the CARRA Legacy Registry. This cohort is not an inception cohort, and thus there could have been selection bias, because those patients with severe disease or mild disease might not have been included. Because subjects were enrolled at any stage of disease, this registry represents a cross-sectional, heterogeneous population. Families with limitations with the English language might have been excluded as well. In addition, many items were selfreported from subjects and families, including income, race, and insurance status, and data collection was often retrospective. Information about when a subject met the diagnostic criteria for JDM was not known; only information on when the first symptom was noted by the parent and when the subject was first seen by a pediatric rheumatologist was collected. More details related to parent education level, subtype of insurance (ie, private vs. Medicaid/government-supported) would have been helpful for evaluating the implications of income and outcomes in JDM. This analysis was not adjusted for multiple comparisons; thus, our results should be viewed as hypothesis-generating rather than hypothesis-testing. The overall model shows a P value < .01 with R 2 = 12.5%. R 2 is a statistical measure of how close the data are to the fitted regression line.
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In conclusion, this study of North American children with JDM enrolled in the CARRA Legacy Registry suggest that minority race and lower income are associated with worse outcomes, increased morbidity, and decreased physical function. Registries such as the CARRA Legacy Registry, aimed at studying rare conditions like JDM are powerful, because they allow us to ask and answer questions beyond the reach of any single rheumatology practice. Prospective, multicenter, longitudinal research is needed to clarify the observations made in this study among different racial and socioeconomic groups. an we remember what we used to think the future would be like? And can we forget about those devices that time has left behind? Goodbye typewriters, adding machines, and soon dictaphones. Fifty years ago in The Journal, Katz and Robinson described the use of the photomograph to time the Achilles tendon reflex children in normal children, hoping that this technology could later be applied to distinguish patients with myxedema and other thyroid dysfunction. In hindsight, this device was not the way of the future. Patients with hypothyroidism have long been characterized as having slow, or "hung-up," deep tendon reflexes. However, the rubber percussion "tomahawk" hammer of the clinical examination is still the gold standard for diagnosis, supplemented by laboratory investigations for thyroid dysfunction.
Indeed, deep tendon reflexes, perhaps better physiologically described as muscle stretch reflexes, are often one of the most overlooked or poorly conducted parts of the pediatric physical examination. Pediatricians would be well served to purchase and use often an inexpensive, typically less than $5, reflex hammer, rather than tapping reflexes with fingers, tongue blades, and stethoscopes. The stretch of the muscle with the striking of the tendon produces the sensorimotor reflex. Reflexes are most commonly classified as 0 absent, 1+ diminished or hard to elicit, 2+ normal, 3+ increased,
